Evidence map›Paper›PMID 42694899›Full record

ReviewReviews in cardiovascular medicine2026

Mesenchymal Stromal Cell Therapy in Cardiovascular Disease: Reconsidering Clinical Inconsistency Through the Mechanism-Endpoint Relationship.

Luca Bonanni, Nicola Ferri

Abstract readReview
In one paragraph

Review in Reviews in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Luca BonanniDepartment of Medicine, Ospedale dell'Angelo, 30174 Venice, Italy.ORCID https://orcid.org/0009-0004-6360-5653
Nicola FerriDepartment of Medicine, University of Padua, 35128 Padova, Italy.ORCID https://orcid.org/0000-0003-1454-1687

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesenchymal stromal cell (MSC) therapy has been investigated for more than two decades as a regenerative approach in cardiovascular disease. Preclinical studies have shown reproducible biological activity; however, clinical translation has been less convincing. Trials in acute myocardial infarction (AMI) and heart failure (HF) have established feasibility and an acceptable safety profile; however, effects on functional and imaging parameters remain modest, and a consistent impact on mortality, hospitalization, and other hard clinical outcomes has not been demonstrated.

Indexed as

clinical trials as topicendpoint determinationextracellular vesiclesheart failureimmunomodulationmesenchymal stromal cellsmyocardial infarctionparacrine communicationregenerative medicinetranslational research

Identifiers

PMID42694899
PMCPMC13540015

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.